OKYO Pharma (OKYO) Receivables (2021 - 2025)

OKYO Pharma (OKYO) has 5 years of Receivables data on file, last reported at $2.1 million in Q1 2025.

• Receivables for Q1 2025 came in at $2.1 million, up 1242.28% year-over-year; the trailing twelve-month figure through Mar 2025 was $2.1 million (up 1242.28% YoY), and the FY2025 annual result was $246842.0, up 56.7% from the prior year.
• Receivables climbed to $2.1 million in Q1 2025 per OKYO's latest filing, from $157523.0 in the prior quarter.
• Over five years, Receivables peaked at $2.1 million in Q1 2025 and troughed at $86741.0 in Q1 2021.
• A 5-year average of $983523.6 and a median of $933043.0 in 2023 frame the typical range for Receivables.
• The sharpest annual moves came in 2022 and 2024: Receivables soared 1774.44% in 2022, then sank 83.12% in 2024.
• A 5-year view of Receivables shows it stood at $86741.0 in 2021, then soared by 1774.44% to $1.6 million in 2022, then plunged by 42.61% to $933043.0 in 2023, then slumped by 83.12% to $157523.0 in 2024, then surged by 1242.28% to $2.1 million in 2025.
• Business Quant data shows OKYO's Receivables at $2.1 million in Q1 2025, $157523.0 in Q1 2024, and $933043.0 in Q1 2023.